Drugs / Altastaph
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00063089 | Sep 2002 → Sep 2004 | staphylococcal infection | Nabi Biopharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Altastaph | “S. aureus capsular polysaccharide immune globulin (Altastaph) is a polyclonal immune globulin preparation that is being developed as adjunctive therapy for persons with S....” PMID 17893153 ↗ Sep 2007 |
| Known as | S. aureus capsular polysaccharide immune globulin | “S. aureus capsular polysaccharide immune globulin (Altastaph) is a polyclonal immune globulin preparation that is being developed as adjunctive therapy for persons with S....” PMID 17893153 ↗ Sep 2007 |
| Modality | Protein / enzyme biologic | “polyclonal immune globulin preparation” PMID 17893153 ↗ Sep 2007 |